PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Types of CLL • Symptoms • Diagnosis • Staging • Management • Key buying criteria PART 06: Pipeline analysis • Acalabrutinib • TG-1101 + ibrutinib • TGR-1202 • Venetoclax + obinutuzumab • Venetoclax + rituximab • REVLIMID • Duvelisib PART 07: Market landscape • Global CLL therapeutics market • Total addressable market for global CLL therapeutics • Five forces analysis PART 08: Market segmentation by ROA • Oral • Parenteral PART 09: Market segmentation by type of molecule • Small molecules • Biologics PART 10: Geographical segmentation • Global CLL therapeutics market by geographical segmentation 2015-2020 • CLL therapeutics market in Americas • CLL therapeutics market in EMEA • CLL therapeutics market in APAC PART 11: Market drivers • Special regulatory designations • Recent drug approvals • Application for expanded indication approvals • Increase in patient pool PART 12: Impact of drivers PART 13: Market challenges • High cost of therapy • Availability of chemotherapy and off-label drugs • Adverse effects of drugs • Stringent regulatory guidelines PART 14: Impact of drivers and challenges PART 15: Market trends • Joint ventures and partnerships • Patient assistance programs • Rise in development of combination therapies • Growing public awareness • PART 16: Vendor landscape • Competitive scenario • Market share analysis 2015 • F. Hoffmann-La Roche • AbbVie • Teva Pharmaceuticals • Johnson & Johnson • Gilead Sciences • Novartis • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Timeline of development of leukemia drugs Exhibit 03: Snapshot of CLL Exhibit 04: Types of CLL Exhibit 05: Main diagnostic procedures to determine presence of CLL Exhibit 06: Other diagnostic procedures to determine presence of CLL Exhibit 07: Rai stages of CLL Exhibit 08: Binet stages of CLL Exhibit 09: Management of CLL Exhibit 10: Key buying criteria for CLL drugs Exhibit 11: Pipeline portfolio: Global CLL therapeutics market Exhibit 12: Percentage share of drug candidates by stage of development 2015 Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions) Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions) Exhibit 15: Five forces analysis Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015 Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015 Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015 Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020 Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions) Exhibit 21: Global CLL therapeutics market by geography 2015-2020 Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions) Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions) Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020 Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions) Exhibit 27: Impact of drivers Exhibit 28: Cost of therapy for CLL Exhibit 29: Impact of drivers and challenges Exhibit 30: SWOT: MabThera Exhibit 31: SWOT: Imbruvica Exhibit 32: SWOT: Treanda Exhibit 33: SWOT of Zydelig Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions) Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015 Exhibit 36: F. Hoffmann-La Roche: Key takeaways Exhibit 37: AbbVie: Key takeaways Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions) Exhibit 39: Teva Pharmaceuticals: Key takeaways Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions) Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions) Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions) Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015 Exhibit 44: Johnson & Johnson: Key takeaways Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions) Exhibit 46: Gilead Sciences: Key takeaways Exhibit 47: Novartis: Key takeaways

F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, Novartis, Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, ZIOPHARM Oncology.